Manish Patel, DO, discusses updates in treatment with a PD1 and CTLA-4 inhibitor in non–small cell lung cancer.
Manish R. Patel, DO
Advertisement
Articles by Manish R. Patel, DO
Manish Patel, MD, DO, discusses choosing a chemoimmunotherapy regimen for patients with advanced, metastatic non–small cell lung cancer.
Manish Patel, DO, discusses the role of CTLA-4 inhibitors in non–small cell lung cancer.
Manish R. Patel, DO, discusses the safety profile of entrectinib in NTRK fusion–positive solid tumors.
Manish R. Patel, DO, discusses the role of entrectinib in gastrointestinal malignancies.
Manish R. Patel, DO, discusses choosing immunotherapy drugs for patients with non–small cell lung cancer.
Manish R. Patel, DO, discusses current questions and research regarding immunotherapy in non–small cell lung cancer.
Advertisement
Latest Updated Articles
Dr. Patel on the Role of Entrectinib in Gastrointestinal MalignanciesPublished: July 1st 2020 | Updated:
Dr. Patel on the Safety Profile of Entrectinib in NTRK+ Solid TumorsPublished: August 28th 2020 | Updated:
Dr. Patel on Ongoing Immunotherapy Research for NSCLCPublished: August 15th 2019 | Updated:
Dr. Patel on Choosing Immunotherapy Drugs for NSCLCPublished: September 19th 2019 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
FDA Advises on Next Steps for Nogapendekin Alfa Inbakicept Plus BCG sBLA in BCG-Unresponsive Papillary NMIBC
3
Ixazomib-Based Regimens Expand Options in Relapsed/Refractory Multiple Myeloma
4
NP-G1-044 Receives FDA Orphan Drug Designation for Pancreatic Cancer
5